1Hardie DG,Scott JW,Pan DA,et al.Management of cellular energy by the AMP-actived protein kinase system.FEBS Lett,2003,546:113-120.
2Saha AK,Avilucea PR,Ye JM,et al.Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.Biochem Biophys Res Commun,2004,314:580-585.
3Buhl ES,Jessen N,Pold R,et al.Long-Term AICAR Administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome.Diabetes,2002,51:2199-2206.
4Cheung PCF,Salt IP,Davies SP,et al.Characterization of AMP-activated protein kinase c-subunit isoforms and their role in AMP binding.Biochem J,2000,346:659-669.
5Minokoshi Y,Kim YB,Peroni OD,et al.Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase.Nature,2002,415:339-343.
6Tomas E,Tsao TS,Saha AK,et al.Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain:Acetyl-CoA carboxylase inhibition andAMP-activated protein kinase activation.Proc Natl Acad Sci U.S.A.,2002,99:16309-16313.
7Halseth AE,Ensor NJ,White TA,et al.Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.Biochem Biophys Res Commun,2002,294:798-805.
8Itani SI,Ruderman NB,Schmieder F,et al.Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol,Protein Kinase C,and IκBα.Diabetes,2002,51:2005-2011.
9McGarry JD.Dysregulation of Fatty Acid Metabolism in the Etiology of Type 2 Diabetes.Diabetes,2002,51:7-18.
10Park H,Kaushik UK,Constant S,et al.Coordinate Regulation of Malonyl-CoA Decarboxylase,sn-Glycerol-3-phosphate Acyltransferase,and Acetyl-CoA Carboxylase by AMP activated Protein Kinase in Rat Tissues in Response to Exercise.J Biol Chem,2002,277:32571-32577.
4Ceriello A, Johns D, widel M, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea ( monorherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes [J]. Diabetes Care, 2005, 28(2): 266-272.
5Gallo A, celotto G, pintonp, et al. Metformin prevents glucose-induced protein kinase-clbetat I activation in human umbilical vein endothelial cells through an antioxidant mechanism [ J ]. Diabetes, 2005, 54(4) : 1123 - 1131.
7HU FB, MEIGS JB, LI TY, et al. Inflammatory markersand risk of developing type 2 diabetes in women[J]. Diabetes, 2004, 53(3) :693-700.
8SPRANGER J, KROKE A,MOHL IGM , et al. Inflammato-ry cytokines and the risk to develop type 2 di-abetes :results of the prespective populationbased European prospective investigation intocancer and nutrition(EP IC Potsdam study[J]. Dia-betes, 2003, 52(3) :812-817.
9IS0DA K , Y0UNG 几,ZIRLIK A,et al. Metformin in-hibits proinflammatory responses and nuclearfactor-kappaB in human vascular wall cells[J]. A-rterioscler Thomb Vase Biol, 2006, 26 (3)6112-6171.
10CERIELL0 A, J0HNSD, WIDE LM, et al. Comparison ofeffect of pioglitazone with metformin or sulf-onylurea (monorherapy and combination therapy)onpost load glycose tolerance test in patients w-ith type 2 diabetes[J]. Diabetes Care,2005,28(2):266—272.
